Latest research
Latest corporate research
Latest tax advantaged reviews
Subscribe to our latest research
What we do
Investment research services
Tax enhanced research services
Bespoke consulting services
About
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
Our team
News & events
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
×
Latest corporate investment research
Detailed company analysis created specifically for investors
Latest tax advantaged research
Product reports for investors and advisors
Latest published research
NB Private Equity Partners
2025 CMD: good returns from low-risk PE model
3rd Dec 2025
Real Estate Credit Investments (RECI)
Investor Day: opportunities aplenty
2nd Dec 2025
Services for corporates
Investment research & analysis
Detailed company analysis created specifically for investors
Bespoke valuation services
Bespoke valuation services
Services for clients with specific needs
Services for funds
Tax advantaged research
Product reports for investors and advisors.
About
About Hardman & Co.
We are the longest-established commissioned research provider.
Insights
Group
Created with Sketch.
Podcasts
Group
Created with Sketch.
Videos
Group
Created with Sketch.
Events
Group
Created with Sketch.
See all news
Group
Created with Sketch.
Podcast
The EIS Navigator
Latest Episode
125: EIS and VC Basics: How venture capital exits work in EIS & VCTs | Kealan Doyle of Symvan Capital
Stay up-to-date with the latest research
Sign up to our newsletter
Our VCT forum is now available to watch on-demand for a limited time -
VCTs – Growing importance in taxing times: Watch on-demand now
Life Sciences research
Chronix Biomedical
Life Sciences
Monitoring treatment, improving outcomes
13 Nov 2018
Redx Pharma
Life Sciences
ROCK2 inhibitors in chronic kidney disease
09 Nov 2018
Stay up-to-date with the latest research
Sign up to our newsletter
Alliance Pharma Plc
Life Sciences
International brands driving performance
07 Nov 2018
ValiRx
Life Sciences
VAL401 Phase II trial completed
01 Nov 2018
Diurnal Group Plc
Life Sciences
Unexpected Phase III trial outcome
17 Oct 2018
Advanced Oncotherapy
Life Sciences
Four components integrated
By
Dr Martin Hall
16 Oct 2018
Diurnal Group Plc
Life Sciences
First commercial revenues
By
Dr Martin Hall
04 Oct 2018
Redx Pharma
Life Sciences
Strategy launch
By
Dr Martin Hall
02 Oct 2018
Allergy Therapeutics plc
Life Sciences
2018 full-year results: solid growth
By
Dr Martin Hall
27 Sep 2018
Oxford BioMedica
Life Sciences
Partnering strategy delivering profitability
20 Sep 2018
Tissue Regenix
Life Sciences
Strategy delivering growth above expectations
By
Dr Martin Hall
14 Sep 2018
Prev
1
...
11
12
13
14
15
...
22
Next
